**S1 Table.** *ERG*s and their sensitivity to inhibition of complement and CD14 in a C5-deficient background.

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** | **Number of transcripts**A | | |
| **Total** | **Reversible** | **Augmentable** |
| ***ERG*s** | 1691B | 1517C | 11D |
| *Up-regulated* | 896 | 819 | 10 |
| *Down-regulated* | 795 | 698 | 1 |
| *FC > 2* E | 394 | 391 | 0 |
| **C3/CD14-DG**F | 1419 | 1414 | 5 |
| **CD14-DG**G | 1202 | 1200 | 2 |
| **C3-DG**H | 140 | 91 | 49 |
| **C5aR-DG**I | 1 | 1 | 0 |

A Genes may count redundantly in different categories.

B Of C5D *ERG*s, 163 were neither reversible (n=1517) nor augmentable (n=11), and, therefore, defined as independent of CD14, C3 and C5a receptor (CD88).

C Reversed by at least one inhibitory strategy, including inhibition with a C5a receptor antagonist

D Not reversible at all

E Fold change expression (FC) in response to *E. coli* above two-fold (FC > 2)

F C3- and CD14-dependent genes (sensitive to combined inhibition of C3 and CD14)

G CD14-dependent genes (sensitive to inhibition of CD14 with anti-CD14)

H C3-dependent genes (sensitive to inhibition of C3 with compstatin)

I C5aR-dependent genes (sensitive to inhibition of C5a receptor 1 (CD88) with C5aR antagonist)